Pharmaceuticals

Lepu Biopharma has granted ArriVent Exclusive License for MRG007, a Potential Best-in-Class ADC for the treatment of Gastrointestinal Cancers

HONG KONG, Jan. 22, 2025 /PRNewswire/ -- Today, Lepu Biopharma Co., Ltd (Stock Code: 02157.HK) announced that it has entered into an exclusive licensing agreement withArriVent BioPharma, Inc. for MRG007, a Potential Best-in-Class antibody- drug conjugate ("ADC") for the treatment of Gastrointesti...

2025-01-22 12:19 4624

Ascletis Announces Positive Results from U.S. Phase Ia Single Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Provides Program Update

* ASC30 oral tablet demonstrated dose-proportional pharmacokinetic (PK) properties and a long half-life (t1/2) up to 60 hours in the single ascending dose (SAD) study of patients with obesity, supporting once-daily or less frequent oral dosing. * ASC30 oral tablet was generally safe and well ...

2025-01-21 19:00 4829

MedAdvisor Solutions' helps pharmacists in Australia deliver more than 115,000 clinical services to patients through Expanded Scope of Practice Pilots in 2024

New case study showcases improved operational efficiency and patient care with enhanced workflow and clinical services for pharmacists MELBOURNE, Australia, Jan. 21, 2025 /PRNewswire/ -- MedAdvisor Solutions, a global leader in patient engagement and pharmacy technology, published its newest cas...

2025-01-21 07:22 2628

SIRPAD - WORLD'S LARGEST RCT INVESTIGATING MAGICTOUCH PTA SIROLIMUS COATED BALLOON COMPLETES PATIENT ENROLMENT

TAMPA, Fla., Jan. 20, 2025 /PRNewswire/ -- Concept Medical Inc . (CMI), a global leader in innovative drug-delivery technology across vascular interventions, proudly announces the successful completion of patient enrolment in the SirPAD Trial, with over 1,250 pat...

2025-01-20 21:44 4500

Innovent and ASK Pharm Jointly Announce NMPA Approval of Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer

SAN FRANCISCO and SUZHOU, China, Jan. 17, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metaboli...

2025-01-17 08:00 6082

Innovent Presents at the 43rd Annual J.P. Morgan Healthcare Conference

Advancing into new stage of sustainable growth and global innovation SAN FRANCISCO and SUZHOU, China, Jan. 17, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines ...

2025-01-17 07:00 4814

Illuccix® Receives European Approval

MELBOURNE, Australia and LIÈGE, Belgium, Jan. 17, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has received a positive decision on the Marketing Authorization Application (MAA) for its prostate cancer PET[1] imaging agent ...

2025-01-17 06:14 4585

Concept Medical Announces First Patient Enrollment in the MAGICAL BTK IDE Trial, Launching its PAD Clinical Program in the United States

TAMPA, Fla., Jan. 17, 2025 /PRNewswire/ -- Concept Medical Inc. , a global pioneer in innovative drug delivery technology, is proud to announce the successful enrolment of the first patient in the "MAGICAL BTK" (Randomized Controlled Trial of MagicTouch PTA – Siro...

2025-01-17 03:15 3544

SEACare 2025 - Your Gateway to Southeast Asia's Thriving Healthcare Market and Strategic Connections

Unlocking Opportunities in Southeast Asia's Healthcare Market KUALA LUMPUR, Malaysia, Jan. 16, 2025 /PRNewswire/ -- SEACare 2025, the Southeast Asia Healthcare & Pharma Show, returns for its 25th edition from 23 to 25 April 2025 at the Malaysian International Trade and Exhibition Centre (MIT...

2025-01-16 19:56 4276

BGI Genomics Empowers Brunei's National Cervical Cancer Prevention Program

SHENZHEN, China, Jan. 16, 2025 /PRNewswire/ -- On January 15, 2025, the Brunei Ministry of Health (MOH), in partnership with Borneo Genomics Innovation (BGIB), a joint venture of BGI Genomics inBrunei, launched the National Cervical Cancer Prevention and Control Program along with the 2025 Nation...

2025-01-16 12:51 3017

Innovent Receives NMPA Breakthrough Therapy Designation for IBI343 (Anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic Cancer

SAN FRANCISCO and SUZHOU, China, Jan. 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...

2025-01-16 08:03 4432

Samsung Biologics presents business updates at 2025 J.P. Morgan Healthcare Conference

- The company to mark new phase of growth at Bio Campus II with the opening of Plant 5 in April - Samsung Biologics to offer ADC services and invest in advanced development and manufacturing capabilities to better address clients' needs INCHEON, South Korea, Jan. 15, 2025 /PRNewswire/ -- Samsung...

2025-01-15 09:40 3164

Axcynsis Therapeutics Receives FDA Clearance for IND Application of AT03-65, a Differentiated CLDN6-Targeting ADC, Powered by AxcynDOT™ Technology

AT03-65 is the first program utilizing AxcynDOT™, a proprietary payload with a differentiated mechanism of action, to enter clinical development SINGAPORE, Jan. 15, 2025 /PRNewswire/ -- Axcynsis Therapeutics Pte Ltd ("Axcynsis"), a privately held biopharmaceutical company specialized in deliveri...

2025-01-15 09:00 2534

Telix Presentation to the 43rd Annual J.P. Morgan Healthcare Conference

MELBOURNE, Australia and INDIANAPOLIS, Jan. 14, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today advises that Dr.Christian Behrenbruch, Managing Director and Group CEO, will be presenting this week at the 43rd Annual J.P. Morgan Healthcare Confe...

2025-01-14 05:43 2505

BioCina and NovaCina Merger Bolsters Global CDMO Industry

ADELAIDE, South Australia and PERTH, Western Australia, Jan. 14, 2025 /PRNewswire/ -- Global Contract Development and Manufacturing Organizations (CDMOs) BioCina and NovaCina announced a strategic merger that will create a powerful brand in biopharmaceutical and small molecule contract manufactur...

2025-01-14 00:43 2943

Dx&Vx Presents a New Paradigm for Next-Generation Infectious Disease Response with the Development of a Universal Vaccine

- Preparing for Phase 2 Global Trials of a Ferritin Platform-Based Virus-Like Particle Universal Coronavirus Vaccine - Based on the Excellent Safety and Immune Response in Phase 1 Clinical Results, with a Plan to Extend Administration Routes and Indications SEOUL, South Korea, Jan. 13, 2025 /PRNe...

2025-01-13 22:00 3433

CBC Group's R-Bridge Announces US$40M Synthetic Royalty-Backed Financing for Mirxes to Advance Global Expansion

-  R-Bridge will provide bespoke financing of US$40 million with a synthetic royalty structure and flexible repayment terms -  Financing will accelerate Mirxes, Singapore -based miRNA tech company's innovation and commercialization of cancer early detection solutions in new markets -  Transacti...

2025-01-13 19:25 3288

Telix Exceeds FY24 Guidance with US$142M Q4 Revenue

MELBOURNE, Australia and INDIANAPOLIS, Jan. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today provides an update on its commercial and operational performance for the quarter ended31 December 2024 (Q4 2024). Sustained revenue growth * Q...

2025-01-13 15:12 3567

Scintimun® Commercialization Partnership with Curium Pharma

MELBOURNE, Australia and LIÈGE, Belgium, Jan. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has entered into an agreement with Curium Pharma for the transfer of marketing and distribution rights for Scintimun® (99m Tc-be...

2025-01-13 13:08 2354

Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform

MELBOURNE, Australia and INDIANAPOLIS, Jan. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has entered into an asset purchase agreement with antibody engineering company ImaginAb, Inc. (ImaginAb) to acquire a pipeline of next...

2025-01-13 06:34 3266
1 ... 31323334353637 ... 186